China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
35.4625
51.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Total Liabilities & Equity
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
|
Total Liabilities & Equity
¥40.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
17%
|
CAGR 10-Years
15%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Liabilities & Equity
¥33B
|
CAGR 3-Years
17%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Total Liabilities & Equity
¥17B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
18%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Liabilities & Equity
¥48.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
19%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Liabilities & Equity
¥54.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
15%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Liabilities & Equity
¥1.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Glance View
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., a leading player in the healthcare sector, has carved a distinguished path through its commitment to innovation and quality. Established in 1992, the company has grown into a comprehensive healthcare provider with a diverse product portfolio that includes traditional Chinese medicine, over-the-counter drugs, and prescription medications. Leveraging its strong distribution network and extensive research and development capabilities, Sanjiu has positioned itself as a trusted brand among consumers and healthcare professionals alike. As the Chinese healthcare market continues to expand, fueled by a growing middle class and increasing health awareness, Sanjiu is well-poised to capitalize on these trends, driving both revenue growth and market share expansion. An investor looking into China Resources Sanjiu will find a company that not only maintains a robust financial foundation but also demonstrates an unwavering focus on sustainable practices and innovation. The company’s strategic partnerships and investments in modern technology, including digital health and telemedicine, further amplify its competitive edge. With a proactive approach to meeting evolving healthcare demands and an eye on regulatory developments, Sanjiu is not just a health-focused enterprise but a forward-thinking entity that embraces change in a dynamic industry. By combining traditional wisdom with modern methodologies, China Resources Sanjiu stands at the intersection of heritage and innovation, offering promising avenues for long-term growth and investor confidence.
See Also
What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
40.7B
CNY
Based on the financial report for Jun 30, 2024, China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Total Liabilities & Equity amounts to 40.7B CNY.
What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
15%
Over the last year, the Total Liabilities & Equity growth was 5%. The average annual Total Liabilities & Equity growth rates for China Resources Sanjiu Medical & Pharmaceutical Co Ltd have been 22% over the past three years , 17% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
